Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

@article{Evans2011NoninvasiveMO,
  title={Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.},
  author={Michael J Evans and Peter M. Smith-Jones and John Wongvipat and Visitacion Navarro and Sae Jong Kim and Neil Harrison Bander and Steven M. Larson and Charles L Sawyers},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2011},
  volume={108 23},
  pages={
          9578-82
        }
}
Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate cancer (CRPC), responses are variable and short-lived. There is an urgent need to understand the basis of resistance to optimize their future use. We reasoned that a radiopharmaceutical that measures intratumoral changes in AR signaling could substantially improve our understanding of AR pathway directed therapies… CONTINUE READING
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-10 OF 84 CITATIONS

FILTER CITATIONS BY YEAR

2009
2018

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 16 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 26 REFERENCES

Antitumour activity of MDV 3100 in castration - resistant prostate cancer : A phase 1 - 2 study

  • HI Scher
  • Lancet
  • 2010

Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer

  • GS Meirelles
  • Clin Cancer Res
  • 2010

Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (2010) Antitumour activity of MDV3100 in castrationresistant prostate cancer: A phase 1-2 study

  • HI Scher
  • Lancet
  • 2010
1 Excerpt

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

  • C Tran
  • Science
  • 2009
1 Excerpt

Phase I trial of the prostate-specific membrane antigendirected immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer

  • MD Galsky
  • J Clin Oncol
  • 2008
1 Excerpt

Similar Papers

Loading similar papers…